Cargando…

Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study

BACKGROUND: A precipitous decline in health status among people recently released from prison is common. In Victoria, Australia, opioid agonist treatment (OAT) in the community involves frequent contact with primary care, potentially facilitating broader use of primary healthcare services. Among a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtis, Michael, Wilkinson, Anna L., Dietze, Paul, Stewart, Ashleigh C., Kinner, Stuart A., Winter, Rebecca J., Aitken, Campbell, Walker, Shelley J., Cossar, Reece D., Butler, Tony, Stoové, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044112/
https://www.ncbi.nlm.nih.gov/pubmed/36978089
http://dx.doi.org/10.1186/s12954-023-00773-2
_version_ 1784913293895270400
author Curtis, Michael
Wilkinson, Anna L.
Dietze, Paul
Stewart, Ashleigh C.
Kinner, Stuart A.
Winter, Rebecca J.
Aitken, Campbell
Walker, Shelley J.
Cossar, Reece D.
Butler, Tony
Stoové, Mark
author_facet Curtis, Michael
Wilkinson, Anna L.
Dietze, Paul
Stewart, Ashleigh C.
Kinner, Stuart A.
Winter, Rebecca J.
Aitken, Campbell
Walker, Shelley J.
Cossar, Reece D.
Butler, Tony
Stoové, Mark
author_sort Curtis, Michael
collection PubMed
description BACKGROUND: A precipitous decline in health status among people recently released from prison is common. In Victoria, Australia, opioid agonist treatment (OAT) in the community involves frequent contact with primary care, potentially facilitating broader use of primary healthcare services. Among a cohort of men who injected drugs regularly pre-imprisonment, we estimated differences in rates of primary healthcare use and medication dispensation between people who did and did not receive OAT post-release. METHODS: Data came from the Prison and Transition Health Cohort Study. Three-month post-release follow-up interviews were linked with primary care and medication dispensation records. Generalised linear models were fit with one exposure (OAT: none/partial/complete) for 13 outcomes relating to primary healthcare use, pathology testing, and medication dispensation, adjusted for other covariates. Coefficients were reported as adjusted incidence rate ratios (AIRR). RESULTS: Analyses included 255 participants. Compared to no OAT use, both partial and complete OAT use were associated with increased rates of standard (AIRR: 3.02, 95%CI: 1.88–4.86; AIRR: 3.66, 95%CI: 2.57–5.23), extended (AIRR: 2.56, 95%CI: 1.41–4.67; AIRR: 2.55, 95%CI: 1.60–4.07) and mental health-related (AIRR: 2.71, 95%CI: 1.42–5.20; AIRR: 2.27, 95%CI: 1.33–3.87) general practitioner (GP) consultations, total medication (AIRR: 1.88, 95%CI: 1.19–2.98; AIRR: 2.40, 95%CI: 1.71–3.37), benzodiazepine (AIRR: 4.99, 95%CI: 2.81–8.85; AIRR: 8.30, 95%CI: 5.28–13.04) and gabapentinoid (AIRR: 6.78, 95%CI: 3.34–13.77; AIRR: 4.34, 95%CI: 2.37–7.94) dispensations, respectively. Partial OAT use was also associated with increased after-hours GP consultations (AIRR: 4.61, 95%CI: 2.24–9.48) and complete OAT use? with increased pathology utilisation (e.g. haematological, chemical, microbiological or immunological tissue/sample testing; AIRR: 2.30, 95%CI: 1.52–3.48). CONCLUSION: We observed higher rates of primary healthcare use and medication dispensation among people who reported partial and complete OAT use post-release. Findings suggest that access to OAT post-release may have a collateral benefit in supporting broader health service utilisation, underscoring the importance of retention in OAT after release from prison.
format Online
Article
Text
id pubmed-10044112
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100441122023-03-28 Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study Curtis, Michael Wilkinson, Anna L. Dietze, Paul Stewart, Ashleigh C. Kinner, Stuart A. Winter, Rebecca J. Aitken, Campbell Walker, Shelley J. Cossar, Reece D. Butler, Tony Stoové, Mark Harm Reduct J Research BACKGROUND: A precipitous decline in health status among people recently released from prison is common. In Victoria, Australia, opioid agonist treatment (OAT) in the community involves frequent contact with primary care, potentially facilitating broader use of primary healthcare services. Among a cohort of men who injected drugs regularly pre-imprisonment, we estimated differences in rates of primary healthcare use and medication dispensation between people who did and did not receive OAT post-release. METHODS: Data came from the Prison and Transition Health Cohort Study. Three-month post-release follow-up interviews were linked with primary care and medication dispensation records. Generalised linear models were fit with one exposure (OAT: none/partial/complete) for 13 outcomes relating to primary healthcare use, pathology testing, and medication dispensation, adjusted for other covariates. Coefficients were reported as adjusted incidence rate ratios (AIRR). RESULTS: Analyses included 255 participants. Compared to no OAT use, both partial and complete OAT use were associated with increased rates of standard (AIRR: 3.02, 95%CI: 1.88–4.86; AIRR: 3.66, 95%CI: 2.57–5.23), extended (AIRR: 2.56, 95%CI: 1.41–4.67; AIRR: 2.55, 95%CI: 1.60–4.07) and mental health-related (AIRR: 2.71, 95%CI: 1.42–5.20; AIRR: 2.27, 95%CI: 1.33–3.87) general practitioner (GP) consultations, total medication (AIRR: 1.88, 95%CI: 1.19–2.98; AIRR: 2.40, 95%CI: 1.71–3.37), benzodiazepine (AIRR: 4.99, 95%CI: 2.81–8.85; AIRR: 8.30, 95%CI: 5.28–13.04) and gabapentinoid (AIRR: 6.78, 95%CI: 3.34–13.77; AIRR: 4.34, 95%CI: 2.37–7.94) dispensations, respectively. Partial OAT use was also associated with increased after-hours GP consultations (AIRR: 4.61, 95%CI: 2.24–9.48) and complete OAT use? with increased pathology utilisation (e.g. haematological, chemical, microbiological or immunological tissue/sample testing; AIRR: 2.30, 95%CI: 1.52–3.48). CONCLUSION: We observed higher rates of primary healthcare use and medication dispensation among people who reported partial and complete OAT use post-release. Findings suggest that access to OAT post-release may have a collateral benefit in supporting broader health service utilisation, underscoring the importance of retention in OAT after release from prison. BioMed Central 2023-03-28 /pmc/articles/PMC10044112/ /pubmed/36978089 http://dx.doi.org/10.1186/s12954-023-00773-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Curtis, Michael
Wilkinson, Anna L.
Dietze, Paul
Stewart, Ashleigh C.
Kinner, Stuart A.
Winter, Rebecca J.
Aitken, Campbell
Walker, Shelley J.
Cossar, Reece D.
Butler, Tony
Stoové, Mark
Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study
title Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study
title_full Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study
title_fullStr Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study
title_full_unstemmed Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study
title_short Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study
title_sort is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? a prospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044112/
https://www.ncbi.nlm.nih.gov/pubmed/36978089
http://dx.doi.org/10.1186/s12954-023-00773-2
work_keys_str_mv AT curtismichael isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy
AT wilkinsonannal isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy
AT dietzepaul isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy
AT stewartashleighc isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy
AT kinnerstuarta isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy
AT winterrebeccaj isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy
AT aitkencampbell isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy
AT walkershelleyj isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy
AT cossarreeced isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy
AT butlertony isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy
AT stoovemark isuseofopioidagonisttreatmentassociatedwithbroaderprimaryhealthcareuseamongmenwithrecentinjectingdrugusehistoriesfollowingreleasefromprisonaprospectivecohortstudy